Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is described as a leading global provider of transformative intelligence, with news that reflects its activities across Academia & Government, Intellectual Property and Life Sciences & Healthcare. Company announcements frequently highlight new AI-powered tools, analytical reports and customer adoptions that illustrate how Clarivate combines enriched data, analytics and workflow software.
Recent news includes the launch of the Web of Science Research Assistant, a generative AI-powered tool that helps researchers conduct natural-language searches, perform literature reviews and explore visualizations based on more than 120 years of publication and citation data. Clarivate also reports on studies such as the Pulse of the Library report, which surveys thousands of librarians worldwide about AI adoption, open science and budget pressures, and on the annual Highly Cited Researchers list, which recognizes researchers whose work has had broad influence based on Web of Science data.
In Intellectual Property, Clarivate issues updates on solutions like IPfolio and Derwent Patent Monitor, including customer selections by organizations such as Nissan Motor Co., Ltd. and FUJIFILM Holdings Corporation. These stories emphasize how IP management platforms and AI-enabled patent review tools support more efficient IP operations and collaboration between IP and R&D teams.
Life sciences and healthcare news often centers on Clarivate analyses such as the Drugs to Watch report and Companies to Watch reports, which identify emerging therapies and innovative companies using integrated, AI-enhanced datasets. Visitors to this news page can follow Clarivate’s product launches, research reports, customer case studies and investor-related announcements to understand how the company is applying data and AI across its core markets.
Clarivate Plc (NYSE:CLVT) has launched the new OFF-X™ platform, an enhanced solution for preclinical and clinical safety intelligence in biopharma. The platform offers a seamless user experience and unique translational insights, delivering important drug and target safety intelligence to proactively identify risks. Fully integrated with Cortellis Drug Discovery Intelligence™, OFF-X™ provides a comprehensive resource for safety information, streamlining processes and enhancing efficiency.
Key improvements include an 80% reduction in loading times for targets, drugs, drug combinations, and adverse events, faster search capabilities, clearer visual design, full-screen visualization, and additional analytic tools. The platform empowers users to monitor and anticipate toxicology and safety signals, mitigate safety liabilities, and de-risk assets across all phases of drug R&D and post-marketing.
Clarivate Plc (NYSE: CLVT) has announced that Richard Roedel will retire from its Board of Directors on December 31, 2024, due to health reasons. Valeria Alberola, a board member since May 2021, is expected to succeed Roedel as Chair of the Audit Committee. Alberola brings over 25 years of global experience in corporate finance, investment banking, sustainable investments, operations, and strategic management consulting.
Alberola previously served as CEO of Zoma Holdings, from January 2019 to March 2024, following her role as COO from 2017 to 2018. She has also held positions as CFO of Bridge Education Group, Inc. and partner at Q Advisors Alberola holds a B.S. in Economics and Business Administration and an M.B.A. from the Kellogg School of Management at Northwestern University.
Clarivate Plc (NYSE: CLVT) has acquired Rowan TELS Corp., the provider of Rowan Patents, an integrated patent drafting and prosecution solution. This strategic move aims to enhance Clarivate's workflow automation solutions beyond its current IP management and intelligence capabilities. The acquisition will enable Clarivate to offer comprehensive, AI-enabled solutions for patent preparation, filing, and prosecution.
The integration of Rowan Patents will help Clarivate advance its strategy to become the central hub for IP management, providing an end-to-end workspace for patent practitioners. This aligns with Clarivate's commitment to simplifying and optimizing IP management in an increasingly competitive global market.
BioWorld, published by Clarivate Plc (NYSE:CLVT), has been honored with nine 2024 APEX Awards for Publication Excellence. This achievement highlights BioWorld's commitment to delivering superior journalistic excellence, data-driven analysis, and cutting-edge digital publishing in the life sciences and healthcare sector.
The awards span various categories, including writing, news, mental health, financial/investment, and economics. Notable wins include Grand Awards in the Writing Category for articles on sepsis testing and spinal cord injury treatment. The recognition underscores BioWorld's leadership in providing important insights into therapeutics development, medical technologies, business deals, and regulatory challenges.
These accolades reflect the BioWorld team's dedication to producing award-winning journalism that resonates with readers and the publishing industry, reinforcing its position as a leader in delivering critical information that drives innovation and improves lives worldwide.
Clarivate Plc (NYSE:CLVT) has announced a partnership with OhioLINK and SearchOhio to develop a new unified library resource sharing experience across Ohio. The collaboration aims to integrate OhioLINK and SearchOhio's existing INN-Reach platforms into a single consortial solution, expected to be implemented by mid-2025.
The new system will provide a seamless user experience for accessing library materials from 45 public library systems and 87 institutions statewide. It will offer an intuitive interface for patrons to discover resources and explore new content, potentially improving learning outcomes. This initiative builds on OhioLINK's 30-year history of leveraging technology for educational support and SearchOhio's commitment to enhancing public library services.
Clarivate Plc (NYSE: CLVT), a global provider of transformative intelligence, has announced it will report its second quarter 2024 financial results on Tuesday, August 6, 2024, before the market opens. The company will release a press release and earnings supplement with financial information on its investor website. Additionally, Clarivate will host a conference call and webcast at 9:00 AM Eastern Time on the same day to review the results. The webcast will be open to all interested parties and may include forward-looking statements.
Clarivate Plc (NYSE:CLVT) has released its annual G20 scorecard, analyzing research and innovation trends across G20 members. The 2024 report, compiled by the Institute for Scientific Information, includes interactive data visualizations and, for the first time, data for the European Union and African Union. Key findings highlight:
- African Union's high collaboration rate and focus on SDGs 1 and 5
- European Union as the largest contributor of papers
- Germany's above-average citation impact and open access publishing
- India's increasing international collaboration
- Mainland China's shifting collaboration patterns
- South Korea's rising collaborations with China and India
- UK's high citation impact and strong international collaboration
- US's strong patent citation impact in various fields
The scorecard aims to provide a comprehensive view of the global research landscape, informing policymakers and research institutions for strategic decision-making.
Clarivate launched a report on the Unitary Patent Court's (UPC) first year of litigation activity. The analysis, based on Darts-ip data, showed consistent monthly infringement filings averaging ten per month. The number of UPC decisions rose 155% in the second half compared to the first half. German divisions dominated infringement cases, with Munich accounting for 37.7%. Six of the top ten plaintiffs were U.S.-based, and major representative firms handled 71.3% of cases. Electrical engineering led in infringement cases with 39.8%, while instruments led in revocation cases at 36%. The ICT industry saw 38.5% of patents asserted before the UPC.
Clarivate has released its MedTech Trends to Watch 2024 report, announcing key trends and challenges in the MedTech sector. Highlighting economic uncertainty, regulatory changes, and supply chain issues, the report also identifies opportunities in AI integration, ambulatory surgical centers, and advancements in technologies like pulsed-field ablation and surgical robotics. The shift from inpatient to outpatient settings for procedures and the impact of GLP-1 receptor agonists are significant. Macro trends such as an aging population and increased healthcare access are driving further innovation and investment. Regulatory changes in Mainland China and supply chain resilience are important areas of focus. The report is based on insights from over 40 analysts covering 80 markets in more than 50 countries.
Clarivate (NYSE: CLVT) released a Global Research Report highlighting the rapid growth in digital health research and innovation. The report, developed by the Institute for Scientific Information (ISI) and the Clarivate Center for IP and Innovation Research, analyzes data from multiple Clarivate portfolios. It reveals a 70-fold increase in digital health academic publications from 2012 to 2022 and identifies nearly 140,000 patent inventions from 2013 to 2022. Key players in the field include organizations like Snap, AstraZeneca, and the Chinese Academy of Sciences. The advancements in AI and digital technologies, such as mobile apps and telemedicine, are driving this growth, improving healthcare delivery and reducing costs. The study builds on initial findings presented at Digital Health 2024 held at Stanford University.